[A Clinical Study of Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Patients with Acquired Severe Aplastic Anemia: Single Center Experience]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2019 May 21

PMID 31104441

Authors

X F Tang

Y F Jing

W Lu

Y Z Huang

N H Wu

Z Luan

Affiliations

Soon will be listed here.

Abstract

To investigate the efficacy of haplotype hematopoietic stem cell transplantation in the treatment of acquired severe aplastic anemia (SAA) in children. The clinical characteristics of 59 pediatric patients with SAA, including 26 cases VSAA, 37males and 22 females, 47 cases typeⅠ and 12 cases typeⅡ, undrerwent haplo-HSCT in our hospital between December 1, 2011 and December 1, 2017 were retrospectively analyzed. Among 59 patients, 56 patients with a median age of 4.5 (1.2-14.8) years and median weight of 43 (12-80) kg underwent their first HSCT and 3 patients underwent their second HSCT. All patients received the following conditioning regimen: busulfan, cyclophosphamide, and rabbit ATG or Bu (-, CTX) , fludarabineand rabbit ATG. The prophylaxis of acute graft versus host disease (aGVHD) was cyclosporine (CsA) , MMF and methotrexate. All patients received bone marrow transfusion on day 01 and peripheral stem cell transfusion on day 02 from haploid donor. The median dose of donor mononuclear cell counts was 15.60 (7.74-21.04) ×10/kg of recipient weight and CD34 cell counts was 4.86 (3.74-7.14) ×10/kg of recipient weight. Neutrophils and platelets of all 59 children were implanted. The median implantation time of granulocytes and platelets were 13 (10-19) d, 19 (9-62) d, respectively. The incidence of grade Ⅰ-Ⅱ aGVHD was 45.76% (27 cases) and grade Ⅲ/Ⅳ 13.56% (8 cases) , The incidence of chronic GVHD was 8.47% (5 cases) , The incidences of CMV and EBV viremia were 59.32% (35 cases) and 28.81% (17 cases) , respectively. The median follow-up was 30 (8-80) months, 57 patients survived with disease free, 2 patients died of GVHD. Both of the estimated 5-year OS and DFS rates were (96.4±2.5) %. Haplo-HSCT could improve the outcomes of SAA children.

References

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

Jeong D, Chung N, Cho B, Zou Y, Ruan M, Takahashi Y . Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2013; 99(4):664-71. PMC: 3971076. DOI: 10.3324/haematol.2013.089268. View

Barone A, Lucarelli A, Onofrillo D, Verzegnassi F, Bonanomi S, Cesaro S . Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells Mol Dis. 2015; 55(1):40-7. DOI: 10.1016/j.bcmd.2015.03.007. View

Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A . Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008; 112(2):415-25. DOI: 10.1182/blood-2007-08-104745. View

Perez-Albuerne E, Eapen M, Klein J, Gross T, Lipton J, Baker K . Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008; 141(2):216-23. PMC: 3164958. DOI: 10.1111/j.1365-2141.2008.07030.x. View

Xu L, Zhang X, Wang F, Mo X, Han T, Han W . Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2016; 52(3):381-387. DOI: 10.1038/bmt.2016.281. View

Champlin R, Perez W, Passweg J, Klein J, Camitta B, Gluckman E . Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007; 109(10):4582-5. PMC: 1885491. DOI: 10.1182/blood-2006-10-052308. View

Marsh J, Ball S, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith E . Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147(1):43-70. DOI: 10.1111/j.1365-2141.2009.07842.x. View

10.

Peinemann F, Bartel C, Grouven U . First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev. 2013; (7):CD006407. PMC: 6718216. DOI: 10.1002/14651858.CD006407.pub2. View

11.

Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J . Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000; 37(1):69-80. DOI: 10.1016/s0037-1963(00)90031-3. View

12.

Wang Y, Chang Y, Xu L, Liu K, Liu D, Zhang X . Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood. 2014; 124(6):843-50. DOI: 10.1182/blood-2014-03-563130. View

13.

Kongtim P, Cao K, Ciurea S . Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation. Adv Hematol. 2016; 2016:4025073. PMC: 4745275. DOI: 10.1155/2016/4025073. View

14.

Hamidieh A, Mozafari M, Noshad S, Alimoghaddam K, Behfar M, Ghavamzadeh A . Matched related donor hematopoietic stem cell transplantation results in a long-term follow-up of a pediatric acquired severe aplastic anemia subset: A stem cell source perspective. Pediatr Transplant. 2015; 19(4):399-407. DOI: 10.1111/petr.12458. View

15.

Xu L, Liu K, Liu D, Han W, Chen H, Chen Y . A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012; 47(12):1507-12. DOI: 10.1038/bmt.2012.79. View

16.

Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S . The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010; 115(13):2704-8. PMC: 2852369. DOI: 10.1182/blood-2009-09-244525. View

17.

Howard S, Naidu P, Hu X, Jeng M, Rodriguez-Galindo C, Rieman M . Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer. 2004; 43(5):545-51. DOI: 10.1002/pbc.20131. View

18.

Ciurea S, Thall P, Milton D, Barnes T, Kongtim P, Carmazzi Y . Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(8):1392-8. PMC: 4506716. DOI: 10.1016/j.bbmt.2015.05.001. View